ZYME Jul 2024 2.500 call
| Previous close | 8.20 |
| Open | 8.20 |
| Bid | 6.90 |
| Ask | 10.20 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 8.20 - 8.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 8 |
GlobeNewswireZymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in
- GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference: Zymeworks’ management will participate in one-on-one meetings on May 15th in Las
Simply Wall St.We Think Zymeworks (NASDAQ:ZYME) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
